What is Low T 99?
Low T 99 operates as a specialized telehealth platform dedicated to the diagnosis and clinical management of low testosterone in men. The company distinguishes itself by streamlining the patient journey, offering a seamless integration of virtual consultations with licensed medical practitioners and nationwide diagnostic testing via Labcorp. By removing traditional barriers to entry, Low T 99 provides a scalable, accessible model for testosterone replacement therapy, addressing a critical gap in the direct-to-consumer healthcare market. Its focus on affordability and convenience has allowed it to capture significant market share, effectively digitizing a segment of the medical industry that historically relied on fragmented, in-person clinical visits.
How much funding has Low T 99 raised?
Low T 99 has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Low T 99
PPP
Public-Private Partnership
What's next for Low T 99?
With the recent influx of capital, Low T 99 is expected to prioritize the expansion of its digital infrastructure and the optimization of its patient acquisition funnel. The strategic focus will likely shift toward enhancing the user experience through advanced telehealth features and potentially broadening its clinical service offerings to address related hormonal health concerns. As the company matures, the emphasis will remain on maintaining regulatory compliance while scaling its nationwide network of diagnostic partners. This late-stage funding serves as a catalyst for long-term sustainability, enabling the firm to solidify its position as a leader in the men's health technology space while navigating the complexities of the evolving telehealth regulatory environment.
See full Low T 99 company page
